^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tepezza (teprotumumab-trbw)

    i
    Other names: AMG 632, AMG632, RG1507, R1507, RV 001, HZN 001, R 1507, RG 1507, RO-4858696, HZN-001, HZN001, R-1507, RG-1507, RO 4858696, RV001, RO4858696, RV-001
    Associations

    News

    Trials
    Company:
    Amgen, Genmab, Roche
    Drug class:
    IGF-1R inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Effectiveness and Safety of Teprotumumab in patients with thyroid eye disease (ChiCTR2500108068)
    P=N/A, N=42, Not yet recruiting, Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital
    New trial
    |
    Tepezza (teprotumumab-trbw)
    2ms
    HZNP-TEP-305: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=89, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tepezza (teprotumumab-trbw)
    2ms
    A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Amgen | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tepezza (teprotumumab-trbw)
    3ms
    Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients (clinicaltrials.gov)
    P=N/A, N=5, Completed, Amgen | Recruiting --> Completed | N=10 --> 5
    Trial completion • Enrollment change • Real-world evidence
    |
    Tepezza (teprotumumab-trbw)
    3ms
    A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Amgen
    New P1 trial
    |
    Tepezza (teprotumumab-trbw)
    4ms
    TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study (clinicaltrials.gov)
    P4, N=313, Active, not recruiting, Amgen | Trial completion date: Apr 2026 --> Jan 2026 | Trial primary completion date: Apr 2026 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    Tepezza (teprotumumab-trbw)
    4ms
    Efficacy and Safety of Teprotumumab N01 Injection in Subjects with Thyroid Eye Disease Exhibiting Significant Extraocular Muscle Inflammation on MRI but with CAS Scores in the Inactive Phase (ChiCTR2500104314)
    P=N/A, N=15, Not yet recruiting, Department of Ophthalmology, West China Hospital, Sichuan University; Department of Ophthalmology, West China Hospital, Sichuan University
    New trial
    |
    Tepezza (teprotumumab-trbw)
    4ms
    Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Amgen
    New trial • Real-world evidence
    |
    Tepezza (teprotumumab-trbw)
    8ms
    Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=7, Recruiting, Shanghai Changzheng Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tevimbra (tislelizumab-jsgr) • Tepezza (teprotumumab-trbw)
    9ms
    Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined with Anti-PD-1 Monoclonal Antibody in Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=7, Not yet recruiting, Shanghai Changzheng Hospital
    New P1 trial
    |
    Tevimbra (tislelizumab-jsgr) • Tepezza (teprotumumab-trbw)
    9ms
    HZNP-TEP-305: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=80, Recruiting, Amgen | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Tepezza (teprotumumab-trbw)
    1year
    A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants (clinicaltrials.gov)
    P1, N=44, Completed, Amgen
    New P1 trial
    |
    Tepezza (teprotumumab-trbw)